Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Leading the way in novel anti-cancer research

19.11.2003


Key AstraZeneca data presented at the AACR-NCI-EORTC meeting



New research presented today at an official AACR-NCI-EORTC* press conference highlights the potential of a new approach to fighting cancer -- inhibition of Aurora kinases. The study, carried out by AstraZeneca, represents part of a body of innovative research and discovery work undertaken by the company as part of a broad based development program of novel cancer therapies. Key research presented this week also includes results from a study combining two agents developed by AstraZeneca: an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and the vascular targeting agent ZD6126.

New frontiers in cancer biology – inhibition of Aurora kinases:


The Aurora kinase family is important in regulating mitosis and cell division. Because these kinases are only expressed in cells that are actively dividing, they could be an important new target in cancer. Aurora kinases are commonly over expressed in breast, colon, pancreas and bladder tumors and this is correlated with poor prognosis in these diseases. AstraZeneca scientists have discovered selective and potent inhibitors of Aurora kinase activity that may have potential application in human cancer treatment. These inhibitors of Aurora kinase are being investigated to ascertain their potential in the treatment of cancer.

"Through cutting-edge research and development, AstraZeneca hopes to achieve a better understanding of Aurora kinases and their regulation, which could in time be a basis for treating or even preventing cancer," said George Blackledge, Vice President, Medical Director of Oncology, AstraZeneca. "This is part of a broad based development program in cell cycle directed therapies."

Leading the way in combining novel anti-cancer approaches:

New pre-clinical research presented at the meeting shows that combining a vascular targeting agent with an EGFR tyrosine kinase inhibitor may result in greater anti-tumor activity than either agent alone. These agents attack the tumor by different mechanisms.

Tumor blood vessels differ significantly from normal blood vessels. The endothelial cells which line their vessel walls retain the characteristics of immature, newly formed dividing cells and appear to depend heavily on a tubulin cytoskeleton to maintain their shape. Vascular targeting agents are designed to disrupt this cytoskeleton, causing the endothelial cells to change shape from flat to round, resulting in damage to the blood vessel lining. This causes vessel congestion and cessation of blood flow. The tumor is thus starved of oxygen and nutrients, while its waste products start to build up to toxic levels. As a result, much of the tumor dies.

The potential of ZD6126, a vascular targeting agent, and an EGFR tyrosine kinase inhibitor to work together in combination as a cancer treatment approach was evaluated in preclinical work being presented today at this meeting. Based on the results seen in these models, clinical investigation of this drug combination is about to begin.

Also presented at the meeting, University of Florida medical scientists reported the results of the combination of ZD6126 with another AstraZeneca novel anticancer agent in development known as ZD6474, an anti-angiogenesis agent. Anti-angiogenesis agents being developed by AstraZeneca are designed to block the vascular endothelial growth factor (VEGF) signaling pathway. This pathway is a critical step in angiogenesis, the process by which tumors stimulate the formation of new blood vessels. Based on results from preclinical studies, clinical investigations of the combination of vascular targeting agents and anti-angiogenesis agents are planned.

Other novel approaches:

AstraZeneca has a broad portfolio of novel cancer agents in early development for the potential treatment of a wide range of tumors. New pre-clinical data on several AstraZeneca novel agents have been presented at the AACR/NCI/EORTC meeting in Boston this week:
  • An oral prenylation inhibitor treatment that prevents the activation of a number of growth promoting proteins and thus prevents cancer cells from dividing (proliferating)
  • An orally active Src kinase inhibitor, which reduces the ability of cancer cells to invade normal tissues, preventing tumors from spreading
  • CDK (cyclin dependent kinase) and Aurora kinase inhibitors, which interfere with crucial steps in cell division and inhibit the proliferation of cancer cells

About AstraZeneca:

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. In the United States, AstraZeneca is a $9.3 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.

For more information about AstraZeneca, please visit www.astrazeneca-us.com

*AACR: American Association for Cancer Research; NCI: National Cancer Institute; EORTC: European Organization for Research and Treatment of Cancer.

Emily Denney | EurekAlert!
Further information:
http://www.astrazeneca.com/

More articles from Health and Medicine:

nachricht The genes are not to blame
20.07.2018 | Technische Universität München

nachricht Targeting headaches and tumors with nano-submarines
20.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>